Inventor
ANDRES PATRICIA
US48 patents
⚠️ This page may combine multiple inventors who share the name “ANDRES PATRICIA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
DERMIRA INC
9 patentsUS9006462B2Apr 14, 2015
Glycopyrrolate salts
DERMIRA INC13 citations91
US9006461B2Apr 14, 2015
Crystalline glycopyrrolate tosylate
DERMIRA INC13 citations91
US8859610B2Oct 14, 2014
Crystalline glycopyrrolate tosylate
DERMIRA INC15 citations91
US8558008B2Oct 15, 2013
Crystalline glycopyrrolate tosylate
DERMIRA INC22 citations91
US10004717B2Jun 26, 2018
Glycopyrrolate salts
DERMIRA INC5 citations82
US9610278B2Apr 4, 2017
Glycopyrrolate salts
DERMIRA INC4 citations82
US9259414B2Feb 16, 2016
Glycopyrrolate salts
DERMIRA INC8 citations82
US10548875B2Feb 4, 2020
Glycopyrrolate salts
DERMIRA INC1 citations71
US10543192B2Jan 28, 2020
Glycopyrrolate salts
DERMIRA INC1 citations71
TAPPER AMY E
4 patentsUS8063227B2Nov 22, 2011
Salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
TAPPER AMY E23 citations91
US8846731B2Sep 30, 2014
Salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
TAPPER AMY E1 citations61
US8829197B2Sep 9, 2014
Salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
TAPPER AMY E1 citations61
US8710087B2Apr 29, 2014
Salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
TAPPER AMY E1 citations61
PARENT STEPHAN D
4 patentsUS8227482B1Jul 24, 2012
Forms of rifaximin and uses thereof
PARENT STEPHAN D13 citations90
US9133217B2Sep 15, 2015
Forms of rifaximin and uses thereof
PARENT STEPHAN D6 citations81
US8507517B2Aug 13, 2013
Forms of rifaximin and uses thereof
PARENT STEPHAN D6 citations81
US8735419B2May 27, 2014
Forms of rifaximin and uses thereof
PARENT STEPHAN D6 citations79
BASF SE
4 patentsUS11634442B2Apr 25, 2023
Methods for the purification of L-glufosinate
BASF SE5 citations84
US11976089B2May 7, 2024
Methods for the purification of L-glufosinate
BASF SE0 citations61
US11897908B2Feb 13, 2024
Methods for the purification of L-glufosinate
BASF SE0 citations61
US11897909B2Feb 13, 2024
Methods for the purification of L-glufosinate
BASF SE0 citations61
KURA ONCOLOGY INC
3 patentsUS12410184B2Sep 9, 2025
Crystalline forms of a menin inhibitor
KURA ONCOLOGY INC1 citations61
US12521396B2Jan 13, 2026
Pharmaceutical compositions comprising a MENIN inhibitor
KURA ONCOLOGY INC0 citations59
US12466835B1Nov 11, 2025
Solid forms of macrocyclic compounds, salts and formulations thereof, and methods of preparing and using the same
KURA ONCOLOGY INC0 citations54
MIRATI THERAPEUTICS INC
3 patentsUS11787819B2Oct 17, 2023
Crystalline salt of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof
MIRATI THERAPEUTICS INC0 citations60
US12286431B2Apr 29, 2025
Crystalline forms of a KRas G12C inhibitor
MIRATI THERAPEUTICS INC0 citations58
US12281113B2Apr 22, 2025
Crystalline forms of a KRas G12C inhibitor
MIRATI THERAPEUTICS INC0 citations58
G1 THERAPEUTICS INC
2 patentsSONG JIANGAO
2 patentsGILEAD SCIENCES INC
2 patentsARTELO BIOSCIENCES INC
2 patentsJOURNEY MEDICAL CORP
2 patentsMILLENNIUM PHARM INC
2 patentsUS11124519B2Sep 21, 2021
Cocrystal forms of ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl) methyl sulfamate, formulations and uses thereof
MILLENNIUM PHARM INC0 citations60
US10072029B2Sep 11, 2018
Crystalline form of a proteasome inhibitor
MILLENNIUM PHARM INC0 citations45
KRONOS BIO INC
2 patentsUS12152037B2Nov 26, 2024
Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as a Syk inhibitor
KRONOS BIO INC1 citations56
US11339168B2May 24, 2022
Crystalline forms of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as Syk inhibitors
KRONOS BIO INC1 citations56